Oxaliplatin (NSC 266046)

Name: Oxaliplatin (NSC 266046)
Brand: Selleck Chemicals
SKU: S1224
Rating: 5 (123 reviews)

For research use only.

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

123 publications

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Selleck's Oxaliplatin (NSC 266046) has been cited by 123 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cancer Cell, 2018, 33(6):1094-1110

PubMed: 29805078 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Nat Microbiol, 2021, 10.1038/s41564-020-00831-6

PubMed: 33432149 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4840

PubMed: 34376661 ( click the link to review the publication )

J Cachexia Sarcopenia Muscle, 2021, 10.1002/jcsm.12703

PubMed: 33956410 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):10

PubMed: 33407548 ( click the link to review the publication )

Cancers (Basel), 2021, 13(5)957

PubMed: 33668827 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2539

PubMed: 34064221 ( click the link to review the publication )

Gigascience, 2021, 10(4)giab026

PubMed: 33871006 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):449

PubMed: 33953166 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):337

PubMed: 33795652 ( click the link to review the publication )

Arch Toxicol, 2021, 10.1007/s00204-021-03119-8

PubMed: 34251499 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(6):8880-8894

PubMed: 33714949 ( click the link to review the publication )

Cell Prolif, 2021, e13031

PubMed: 33755268 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(11):2756-2769

PubMed: 34345205 ( click the link to review the publication )

J Neurochem, 2021, 156(5):642-657

PubMed: 32654140 ( click the link to review the publication )

Front Oncol, 2021, 11:667689

PubMed: 34123833 ( click the link to review the publication )

Front Pharmacol, 2021, 12:689767

PubMed: 34093212 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 544:65-72

PubMed: 33524870 ( click the link to review the publication )

Biomed Res Int, 2021, 2021:9986376

PubMed: 34212047 ( click the link to review the publication )
Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Genet Test Mol Biomarkers, 2021, 25(4):284-292

PubMed: 33877891 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

STAR Protoc, 2021, 2(2):100574

PubMed: 34142099 ( click the link to review the publication )

ACS Nano, 2020, 28;14(4):5075-5089

PubMed: 32283007 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4815-4827

PubMed: 32907836 ( click the link to review the publication )

J Control Release, 2020, 319:213-221

PubMed: 31899270 ( click the link to review the publication )

J Hematol Oncol, 2020, 1;13(1):40

PubMed: 32357935 ( click the link to review the publication )

Oncogene, 2020, 39(5):987-1003

PubMed: 31591478 ( click the link to review the publication )

Cancer Lett, 2020, 28;476:67-74

PubMed: 32061752 ( click the link to review the publication )

Cancer Lett, 2020, 473:74-89

PubMed: 31904482 ( click the link to review the publication )

Acta Biomater, 2020, S1742-7061(20)30751-0

PubMed: 33388439 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(5):E1118

PubMed: 32365785 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2580

PubMed: 32927726 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):822

PubMed: 33009373 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Cells, 2020, 9(9)E2110

PubMed: 32948057 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-0133

PubMed: 32029633 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Cell Discov, 2020, 21;6:21

PubMed: 32351703 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:473

PubMed: 33005106 ( click the link to review the publication )

Front Pharmacol, 2020, 11:597520

PubMed: 33343368 ( click the link to review the publication )
Front Pharmacol, 2020, 10;11:252

PubMed: 32210825 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-020-04187-w

PubMed: 33169187 ( click the link to review the publication )

Photochem Photobiol, 2020, 96(2):365-372

PubMed: 31820435 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(7):3659-3667

PubMed: 32620605 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

BMC Complement Med Ther, 2020, 11;20(1):141

PubMed: 32393373 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Cell Rep Med, 2020, 1(9):100160

PubMed: 33377131 ( click the link to review the publication )

Theranostics, 2020, 10(5):1981-1996

PubMed: 32104496 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):663-670

PubMed: 31897182 ( click the link to review the publication )

Mol Genet Genomic Med, 2020, e1409

PubMed: 32748564 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13988

PubMed: 32814794 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:1625-1635

PubMed: 32110058 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Adv Sci (Weinh), 2019, 6(21):1900667

PubMed: 31728273 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

Biomaterials, 2019, 222:119421

PubMed: 31494503 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1004-2

PubMed: 31530934 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 14;38(1):196

PubMed: 31088567 ( click the link to review the publication )
Cell Death Dis, 2019, 10(8):600

PubMed: 31395855 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1533-1543

PubMed: 31301362 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31572672 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz032

PubMed: 31065671 ( click the link to review the publication )

Int J Mol Sci, 2019,

PubMed: 31455014 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10845

PubMed: 31350465 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Hum Vaccin Immunother, 2019, 10.1080/21645515.2019.1665960

PubMed: 31584324 ( click the link to review the publication )

Oncol Lett, 2019, 17(6):5023-5029

PubMed: 31186713 ( click the link to review the publication )

Oncol Lett, 2019, 5(3):935-942

PubMed: 23426424 ( click the link to review the publication )

Neoplasma, 2019, 66(1):39-45

PubMed: 30509090 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 10.1007/s13402-019-00471-x

PubMed: 31493144 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2237

PubMed: 29884866 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Elife, 2018, 7e32838

PubMed: 29417930 ( click the link to review the publication )

Cell Death Discov, 2018, 4:116

PubMed: 30588338 ( click the link to review the publication )

Oncoimmunology, 2018, 7(5):e1424676

PubMed: 29721389 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2018, 356:159-171

PubMed: 30086361 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):844-854

PubMed: 29749542 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )
Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560127 ( click the link to review the publication )

Theranostics, 2018, 8(5): 1312–1326

PubMed: 29507622 ( click the link to review the publication )

Oncotarget, 2018, 9(45):27835-27850

PubMed: 29963241 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

J Cancer, 2017, 8(17):3555-3566

PubMed: 29151941 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):15-25

PubMed: 27671335 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Cell, 2017, 170(3):548-563

PubMed: 28753429 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Cancer Lett, 2016, 380(1):87-97

PubMed: 27322737 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(11):1428-1438

PubMed: 27984028 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1772-9

PubMed: 27613096 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(10):1350-65

PubMed: 26290450 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31272-83

PubMed: 26418718 ( click the link to review the publication )

Int J Cancer, 2014, 136(4):E51-61

PubMed: 25156627 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )

J Biomed Opt, 2014, 19(11):116001

PubMed: 25364948 ( click the link to review the publication )
ACS Chem Biol, 2013, 8(12):2771-7

PubMed: 24093441 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

Optical Methods for Tumor Treatment and Detection, 2013, 10.1117/12.2010730

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[9]

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Caco2	MV;GeY5kfGmxbjDBd5NigQ>?	MWmzNE8yODEEoN88US=>	NF\J[\|YyPsLiaB?=	NHnNdZZFVVOR	NFexeGRi[3SrdnH0[ZMhVnKoMh?=	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2	MYfGeY5kfGmxbjDBd5NigQ>?	M3z1SVMwOTBxM{Cg{txO	NGW4W4EyPiCq	Mon2SG1UVw>?	NUDocIR3cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>?	MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2	NVXy[G5xTnWwY4Tpc44hSXO\|YYm=	M2L3dlMxyqEQvF2=	M4DQR\|I1KGh?	MYfEUXNQ	M3rSdIlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gTG8uOSxiQVvSNWMtKGGwZDDOVW8y	Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
SW620	NYXOe5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\wRWIyOC15MDDt[{9N	MknrNlQwPDhxN{KgbC=>		MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M1iyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkS2N\|A2Lz5{NE[0OlMxPTxxYU6=
SW480	NIj5S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFPmdZI1QCCqwrC=		NWiwZ2JIUUN3ME2yNE45KHWpL33M	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{ME[3OUc,OjR5MkC2O\|U9N2F-
HCT116	NVnpN3FsTnWwY4Tpc44hSXO\|YYm=	MnXENk82KML3TR?=	M17VWVI1NzR6IHi=		NYfreZVDe3WycILld5NmeyC\|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MUSxNUc,OjR5NkG0NVE9N2F-
HT-29	NWrpNZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjTdXRuOcLizszN	MYCwMVczKGh?		NVjyW2xVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\qb\|HDqM7:TR?=	NYDxZ2U3OC15MjDo		NXfDSm53cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XRO2lEPTB;MUGuN\|DDqMLzwrCxMlAzKM7:TR?=	NIHFU4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
HEK293	NXniWmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3hSJZWUUN3ME24MlgzyqEEsdMgOU42QSEQvF2=	Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HT-29	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnlV3ZKSzVyPkWwJO69VQ>?	M3u1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HCT-116	M3vDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvzTWM2OD14LkK0xsDDucLiMj65O{DPxE1?	MlnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
MCF-7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvXU3A3UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN	M1zU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HepG2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKzN2NKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2=	NHHJe5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
A549	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;Ib2ZNUUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
SGC7901	M4Hid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzjbYExUUN3ME2yNU44O8LiwsJCpFMvODhizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
COC1	NIfZcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX6O3U{UUN3ME20Ok4zOMLiwsJCpFMvOTRizszN	MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlL1O\|IhcMLi		NHq0cFNKSzVyPU[uNlPDuTBwN{WgxtVoN22O	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV\|NkC2N\|E9N2F-
SW480	NGnGPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2HteVczKGkEoB?=		NVHSNmlHUUN3ME2xNE44yrF{LkK2JOK2\y:vTB?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV\|NkC2N\|E9N2F-
MIAPaCa-2	M2rTdmZ2dmO2aX;uJGF{e2G7	NVXlNJBCOjYkgJpCuW0>	MWqyOE81QCCq		NXfOT5d[cW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG\|ZT2zxsA>	MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1	M1rxXGZ2dmO2aX;uJGF{e2G7	NXjiUnZKOjYkgJpCuW0>	MVyyOE81QCCq		MnTDbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1\|wrC=	Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2	MnrkRZBweHSxc3nzJGF{e2G7	MWOyOgKBkcL3TR?=	MYiyOEBp		NWi0fW9[cW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?=	NGHado89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
Panc-1	M4rNU2Fxd3C2b4Ppd{BCe3OjeR?=	M1fSb\|I26oDLwsXN	NXruSnpmOjRiaB?=		MlLEbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC\|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>?	M1nQVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
HPDE	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFv0U4gzPS93MDFOwG0>	NUjRZVF4OjRxNEigbC=>		MmLLbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
SW1990	M2HUOmNmdGxiVnnhZoltcXS7IFHzd4F6	NWX1SGV7OjVxNUCg{txO	MmjyNlQwPDhiaB?=		NUDI[2VXcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m\|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD	M2jMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
MIAPaCa-2	MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmL5NlUwPTBizszN	NIfTUpYzPC92ODDo		Ml[2bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYHMV5hnOjVxNUCg{txO	NULyPVFWOjRxNEigbC=>		MmrabY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP	NYrk[nNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17aU2lEPTB;MUiuOkDDuSBzLkKg{txO	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
A549	NGHoZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTVwODFCtUAxNjZizszN	MkGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
SW480	NXK0UnU4TnWwY4Tpc44hSXO\|YYm=	NX63XoFLOTEkgJpCuYcwdWx?	NWfBV3RwOjUkgJno		MUnlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh?	NXz2bpRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFk1OjBpPkK1O\|Q6PDJyPD;hQi=>
SW620	Moe1SpVv[3Srb36gRZN{[Xl?	NIjEWJoyOOLCidM1[{9udA>?	NYrvPGtYOjUkgJno		NFHBU3ZmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi=	NF2ySVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW480	M1;QUGZ2dmO2aX;uJGF{e2G7	NWf0N2UzOTEkgJpCuYcwdWx?	NEPuV3czPOLCiXi=		MoPXbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>?	NHficlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620	M3v5N2Z2dmO2aX;uJGF{e2G7	M3zrU\|Ex6oDLwsXnM41t	M4jqeFI16oDLaB?=		NYnGVVFxcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?=	M3Hm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
HT-29	M2L5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV6zb49{UUN3ME21MlIzKM7:TR?=	NV\GXHVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O\|YyPDd7PD;hQi=>
SNU-175	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\WTWM2OD1zLkWxJO69VQ>?	NUHvUpJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O\|YyPDd7PD;hQi=>
COLO-320DM	NH\6N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjXTWM2OD13LkO4JO69VQ>?	MnK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
DLD-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\HbXJqUUN3ME24MlY2KM7:TR?=	M4\1RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DiFi	NWrIO5J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfBTWM2OD1zMD65OUDPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O\|k9N2F-
HCT-15	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRThwNkSg{txO	NFjwPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDBN5RKSzVyPUG3MlUh\|ryP	NITPZ3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
TMK-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnZSHNYUUN3ME2yNk43KM7:TR?=	NF7mSIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
MKN-45	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmL5TWM2OD1zND6wJO69VQ>?	NVrDVW1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFkxPTdpPkK1O\|g6ODV5PD;hQi=>
AGS	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\4TWM2OD1zMD62JO69VQ>?	NFnxT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXLSmVTUUN3ME21N{42KMLzIEGuOUDPxE1?	NXzQbWtnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
SiHa	NWjTVZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTBwODFCtUAxNjFizszN	Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEGwNFcoRjJ3OECxNFA4RC:jPh?=
HT-29	NILCZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTN3Lk[g{txO	NWLtdW03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFMxQDVpPkK2NFA{ODh3PD;hQi=>
DLD-1	M1fHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYezXGpPUUN3ME2zNk4zKM7:TR?=	Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMEOwPFUoRjJ4MECzNFg2RC:jPh?=
HT29	NWXZd3NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nmb2lEPTB;NkOg{txOKMLzIEG4	M{Lhc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38	M3XCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH6UZJ5UUN3ME2yN{DPxE1iwsGgNi=>	M4XNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
SW620	M3LKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPwTWM2OD1\|Lk[4JO69VQ>?	NEiyRlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
SW480	NX3mPGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2OyRWlEPTB;Mj64OkDPxE1?	M{T4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
RKO	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFwMkOg{txO	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
LoVo	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwMjFOwG0>	M2S1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
KM12	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2D1RWlEPTB;ND6zO{DPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116p53-	M4HEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXUTWM2OD1zLkC4JO69VQ>?	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
HCT116	M4GwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLN[oI2UUN3ME2xMlA1KM7:TR?=	M{jiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HCT15	NGPZNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwNEOg{txO	M4KzclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HT29	M4jsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwNkmg{txO	M1\2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
DLD1	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJwMEGg{txO	NVvZPHBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
Colo205	NGWwVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjoTWM2OD1\|LkOzJO69VQ>?	Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHMTWM2OD1\|LkOzJO69VQ>?	NFq0UFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
CT26	NWntemZiS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2PNU\|QhdU1?	MoDLOFghcMLi		Mn[w[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITvJFU{NjJn	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{CxNkc,OjZzM{ewNVI9N2F-
CT26	NWnkdFFGTnWwY4Tpc44hSXO\|YYm=	NITTbnQ1KG2P	MmD5OFghcMLi		Ml:ybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR\|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV?	NFXibZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|AyOid-Mk[xN\|cxOTJ:L3G+
CT26	NXnzXXJLTnWwY4Tpc44hSXO\|YYm=	NHTQTFg1KG2P	NFm4NVU1QCCqwrC=		M1LLVIlv\HWlZYOgZZV1d3CqYXf5	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{CxNkc,OjZzM{ewNVI9N2F-
SK-OV-3	M3XEV2Z2dmO2aX;uJGF{e2G7	NFHUTYY2OCEQvF5CpC=>	NFHEPVY1QCCqwrC=		NFTnepdxem:vb4Tld{B{\W6\|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=>	M2\1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5	MXrGeY5kfGmxbjDBd5NigQ>?	M4jR[FIxKM7:TdMg	MVuyOIg>		NFS0SIVxem:vb4Tld{B{\W6\|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=>	MoXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
PA-1	MYLGeY5kfGmxbjDBd5NigQ>?	NUfmdYlHOTBizszNxsA>	MYiyOIg>		M1TkepBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
SK-OV-3	NWT1SHFXTnWwY4Tpc44hSXO\|YYm=	NUezTIVKPTBizszN	NHTnPWg6PiCq		NX3MdpUxfXBvcnXneYxifGW\|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K\|	M2ThdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5	MXfGeY5kfGmxbjDBd5NigQ>?	M{nCRVMxKM7:TR?=	NGiwO5g1QGh?		NEDFUWF2eC2{ZXf1cIF1\XNidHjlJJN1emW\|czDsbYdidmS\|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
PA-1	MVLGeY5kfGmxbjDBd5NigQ>?	MmnYNVAh\|ryPwrC=	MkLqOFhp		M1r1TpVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO\|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>?	MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3	MYTGeY5kfGmxbjDBd5NigQ>?	MYK1NEDPxE1?	MYS5OkBp		Ml\neJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz	M3nkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5	MWDGeY5kfGmxbjDBd5NigQ>?	MnzlN\|Ah\|ryP	M{TOU\|Q5cA>?		MlnJeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz	NF7yWoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
PA-1	M1P5[GZ2dmO2aX;uJGF{e2G7	MkLVNVAh\|ryPwrC=	NYjU[lVZOjSq		M4TjRpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=>	NYfZTGdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3	NHfscIVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHzVVIQxNTFyMDFOwG0>	NHHkV2gzPC92OD:3NkBp		NHSwVJFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NEHRNVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
OVCAR-5	M{WwZWNmdGxiVnnhZoltcXS7IFHzd4F6	NHTKU4UxNTZyIN88US=>	MV:yOE81QC95MjDo		MmPJbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
PA-1	Mk\nR4VtdCCYaXHibYxqfHliQYPzZZk>	M{joWlAuOjBizszN	NI\mVZAzPC92ODDo		NFzPemNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
HCT116	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTpU5NOUUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2=	M{jXSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
HT29	NYC1emE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[zdJZKSzVyPUCuPFjDqMLzwrCwMlIh\|ryP	M2\wUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
SNU-387	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\BeGNKSzVyPUK1xsDDucLiMj63JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
SNU-475	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjWSZFWUUN3MP-8olMxKM7:TR?=	M1jxd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
Hep-G2	NFi2R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkO5TWM2OD1zMz6xxsDDucLiMT62JO69VQ>?	M2K4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
SNU-398	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPZUHhKSzVyPU[uOeKhyrIEoEGuNUDPxE1?	NFzuNIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo	MX\GeY5kfGmxbjDBd5NigQ>?	M2jCUVEwPSEQvF2=	M3XFUVI1NzR6IHi=		Mn7WbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?=	M2nhNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC4OVI{Lz5{NkKwPFUzOzxxYU6=
HCT116 p53+/+	M1;5SGZ2dmO2aX;uJGF{e2G7	NUnNZoNnOS93IN88US=>	NXXKRW5SOjRxNEigbC=>		MmDkbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?=	NFqzXnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
MDA-MB-231	NITjTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDYWpZKSzVyPUKzMlEhyrFiMD6xJO69VQ>?	MmDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
MCF-7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDqcVRKSzVyPUG1MlQhyrFiMD6zJO69VQ>?	NFrO[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNVU6OSd-Mk[yNVE2QTF:L3G+
SK-BR-3	M1[xWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTXTWM2OD1\|MT6wJOKyKDBwMTFOwG0>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
LoVo	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWO0PEBpyqB?		MW\JR\|UxRTl2LkizJO69VQ>?	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O\|U6RC:jPh?=
HCT116	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlPaOFghcMLi		MXPJR\|UxRTFzLki2JO69VQ>?	Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O\|U6RC:jPh?=
SW480	NEOzfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2HVRVQ5KGkEoB?=		MnP2TWM2OD1zLki3JO69VQ>?	NE\SN3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2PVc2QSd-Mk[yOlk4PTl:L3G+
CaES-17	NXjiZ2drS3m2b4TvfIlkcXS7IFHzd4F6	NWfBOHlFOOLCk{G2NOKh\|ryP	MVu0POKhcA>?		MWDJR\|UxRTVwNdMgxtHDqDBwMjFOwG0>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
HKESC-2	NF22TopEgXSxdH;4bYNqfHliQYPzZZk>	NX7OSHBiOOLCk{G2NOKh\|ryP	NWC1O5RPPDkEoHi=		M3n2c2lEPTB;NT64xsDDucLiMD61JO69VQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	VEGFR-1 / NRP-1 ; PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min. p-Src(Y418) / p-FAK(Y861) ; PubMed: 19383922 Cancer Res Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	18790786 19383922
Immunofluorescence	E-cadherin / Vimentin; PubMed: 30787271 Cell Death Dis Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells. ATXN2L / G3BP1; PubMed: 30787271 Cell Death Dis Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules.	30787271
Growth inhibition assay	Cell viability ; PubMed: 28339092 Oncol Rep Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations.	28339092

In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]

Protocol

Cell Research:

^[4]

- Collapse

Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
Concentrations: ~100 μM
Incubation Time: 48 hours
Method:
The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

(Only for Reference)

Animal Research:

^[6]

- Collapse

Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
Dosages: 10 mg/kg
Administration: A weekly i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	3 mg/mL warmed (7.55 mM)
	DMF	Insoluble
	Ethanol	''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Oxaliplatin (NSC 266046) SDF

Molecular Weight	397.29
Formula	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3
Storage	2 years 4°C(in the dark) powder
Synonyms	L-OHP, Eloxatin
Smiles	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05025826	Not yet recruiting	Other: Phycocare\|Other: Placebo	Metastatic Gastric Cancer	Nantes University Hospital\|Algosource	November 5 2021	Not Applicable
NCT05031975	Not yet recruiting	Drug: Irinotecan\|Drug: Temozolomide	Colorectal Cancer	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	November 1 2021	Phase 2
NCT04944550	Recruiting	--	Upper Urinary Tract Urothelial Carcinoma\|Nephroureterectomy\|Tumor\|Xenograft Model	Centre Hospitalier Universitaire de Nīmes\|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5	March 1 2021	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?
Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin (NSC 241240)

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.
Cytarabine (U-19920A)

Cytarabine (U-19920A， Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabine induces autophagy and apoptosis.

Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Choose Your Country or Region

By Signaling Pathways

By product type

Oxaliplatin (NSC 266046)